top of page
Our Pipeline
3R Pharma is dedicated to developing ophthalmic cannabinoids aimed at treating conditions that impact the lid margin and ocular surface. Our innovative method addresses inflammation, a significant factor evaporative dry eye and blepharitis.
Pharma Pipeline
Blepharitis
R&D
Pre-Clinical
Phase I​
Phase II
Meibomian Gland Disfunction
R&D
Pre-Clinical
Phase I​
Phase II
Our Partners
We have partnered with CanNegev Incubator that was established as a joint venture of Perrigo/Padagis, BOL Pharma, OurCrowd, and Israeli Innovation Authority, and received seed funding from the Israeli Innovation Authority to initiate our research.
bottom of page